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Background: Increasing multidrug-resistance in bacteria resulted in a greater need to find alternative antimicrobial
substances that can be used for clinical applications or preservation of food and dairy products. Research on
antimicrobial peptides including lipopeptides exhibiting both narrow and broad spectrum inhibition activities is
increasing in the recent past. Therefore, the present study was aimed at isolation and characterization of
antimicrobial lipopeptide producing bacterial strains from fecal contaminated soil sample.
Results: The phenotypic and 16S rRNA gene sequence analysis of all isolates identified them as different species of
Gram-negative genera Citrobacter and Enterobacter. They exhibited common phenotypic traits like citrate utilization,
oxidase negative and facultative anaerobic growth. The HPLC analysis of solvent extracts obtained from cell free
fermented broth revealed the presence of multiple antimicrobial lipopeptides. The comprehensive mass spectral
analysis (MALDI-TOF MS and GC-MS) of HPLC purified fractions of different isolates revealed that the lipopeptides
varied in their molecular weight between (m/z) 607.21 to 1536.16 Da. Isomers of mass ion m/z 984/985 Da was
produced by all strains. The 1495 Da lipopeptides produced by strains S-3 and S-11 were fengycin analogues and
most active against all strains. While amino acid analysis of lipopeptides suggested most of them had similar
composition as in iturins, fengycins, kurstakins and surfactins, differences in their β-hydroxy fatty acid content
proposed them to be isoforms of these lipopeptides.
Conclusion: Although antimicrobial producing strains can be used as biocontrol agents in food preservation,
strains with ability to produce multiple antimicrobial lipopeptides have potential applications in biotechnology
sectors such as pharmaceutical and cosmetic industry. This is the first report on antibacterial lipopeptides
production by strains of Citrobacter and Enterobacter.
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Various species of genera like Clostridium, Escherichia,
Listeria, Salmonella, Shigella, Staphylococcus and Vibrio
[1,2] are known to cause food spoilage. In addition, diffe-
rent drug resistant strains of Escherichia and Salmonella
belonging to family Enterobacteriaceae are reported to
cause food-borne illness [3-6]. Increasing multidrug-
resistance in bacteria resulted in a greater need to find
alternative antimicrobial substances that can be used for* Correspondence: suresh@imtech.res.in
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reproduction in any medium, provided the orvarious applications including clinical as well as preserva-
tion of food and dairy products. Therefore, research on
antimicrobial peptides including antimicrobial biosurfac-
tants as a new class of drugs has increased in the recent
past as they exhibit both narrow and broad spectrum
inhibition activities against Gram-positive and Gram-
negative bacteria or fungi. Although members of the
Enterobacteriaceae family are known to produce bacterio-
cins such as enterocins by Enterobacter sp. [7], serracin by
Serratia sp. [8] bacteriocin by Citrobacter sp. [9] and
microcins by Escherichia sp. [10], they are not reported to
produce any antimicrobial biosurfactants. The different
types of biosurfactants with antimicrobial activity include
lipopeptides, glycolipids, phospholipids and lipopolysaccha-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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different species of the genus Bacillus are reported to
produce diverse antimicrobial lipopeptides with different
applications in pharmaceutical and food processing indus-
tries [12], only few lipopeptides have been reported to
produce by Gram-negative bacteria like Pseudomonas [13].
The lipopeptides produced by Gram-positive strains have
been classified into various types based on their amino acid
composition and fatty acid chain length [14]. Similarly,
lipopeptides of Pseudomonas also have been grouped into
different groups including amphisin, syringomycin, tolaasin
and viscosin based on the number and composition of
amino acids [13,15,16]. Among the several types of
biosurfactants, lipopeptides belonging to iturins [17],
surfactins, [18], fengycins [19], kurstakins [20], bacillomy-
cins [21] and mycosubtilin [22] displayed therapeutic appli-
cations [23] and they were never reported to produce by
any Gram-negative bacteria. Therefore, in the present study
we have isolated few Gram-negative bacterial strains
belonging to genera Citrobacter and Enterobacter produ-
cing antimicrobial lipopeptides from a fecal contaminated
soil sample. Further, detailed characterization of these
antimicrobial lipopeptides assigned them to iturins, fengy-
cins, kurstakins and surfactins, usually produced by Gram-
positive bacteria.
Results
Identification of the lipopeptide producing strains
Nine antimicrobial producing strains were isolated from
a fecal contaminated soil sample during a screen to
isolate the bacteriocin producing bacteria. The colonies
were selected based on colony morphology and the zone
of clearance in their surroundings that might be formed
due to the activity of antimicrobial substances producedFigure 1 Screening of isolates for antimicrobial activity. (A) colonies sh
Selected colonies were purified and preserved. Further, methanol extracts w
isolates and tested against S. aureus (MTCC1430).by the strain (Figure 1A). The isolates grew well on
tryptone soya agar (TSA) between pH 5.0 to 9.0 and up
to 42°C temperature with optimum growth at 37°C. All
strains were rod shaped, facultative anaerobes, showed
positive reaction to catalase and negative for oxidase
activities. The 16S rRNA gene sequence BLAST analysis
revealed high identity with Citrobacter farmeri for
strains S-3, S-6 and S-7. Other strains including S-4, S-5
and S-9 had identity with different species of the genus
Enterobacter. Strains S-10, S-11 and S-12 showed high
similarity with E. cloacae subsp. dissolvens. Further,
Phylogenetic analysis with close relatives also assigned
them to genera Citrobacter and Enterobacter of the
family Enterobacteriaceae. In neighbour-joining phylo-
genetic tree, strains S-3, S-6 and S-7 formed a cluster
with C. farmeri and C. amalonaticus (Figure 2). Al-
though isolate S-9 showed 98.1% identity with E. mori in
16S rRNA gene blast analysis, it formed an out group to
the clade containing E. hormaechei and E. mori with low
bootstrap value. Overall, most of the clusters of the
neighbour-joining phylogenetic tree showed low boot-
strap values.
Isolation and antimicrobial activity of lipopeptides
The methanol extracts of lipopeptides obtained from
different strains (mentioned as sample S-3 to S-12) were
tested for antimicrobial activity using Staphylococcus
aureus (MTCC1430) as test strain (Figure 1B) and sub-
sequently purified using RP-HPLC. Methanol extract of
each sample showed multiple peaks during their HPLC
analysis and the number of peaks differed for individual
strain. The extract obtained from strain S-3 yielded a
maximum number of six peaks followed by strains S-11
and S-5. Individual lipopeptides (fractions) collectedowing zone of clearance (B) well diffusion assay of methanol extracts.
ere prepared from 48 h cell free fermented broth of all selected
Figure 2 Neighbour-joining phylogenetic tree of 16S rRNA gene sequences of all strains showing the relationship with members of
the genera Citrobacter and Enterobacter. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary
distances used to infer the phylogenetic tree.
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to find their antimicrobial activity against Gram-positive
and Gram-negative test strains. Though, S. epidermidis
(MTCC435) and Pseudomonas aeruginosa (ATCC27853)
were taken as representative Gram-positive and Gram-
negative indicator strains initially, subsequently antimicro-
bial activity was tested against S. aureus, Micrococcus
luteus (MTCC106) and Candida albicans (MTCC1637).
Majority of fractions showed activity towards Gram-
positive indicator strains (Figure 3A) and variations
observed in relative sensitivity of Gram-negative test strain
towards different antimicrobial lipopeptide fractions
(Figure 3B). Overall, lipopeptide fractions obtained from
strains S-3 and S-11 showed highest activity against test
strains. In particular, fractions Fr-c and Fr-e of strain S-
11 exhibited maximum antimicrobial activity against S.
aureus and M. luteus at lower concentrations by
inhibiting the complete growth, however, none of the
lipopeptides inhibited the growth of yeast like C.
albicans (data not shown).Determination of minimum inhibitory concentration (MIC)
and sensitivity
The MIC analysis of purified lipopeptide fraction Fr-c of
strain S-11 revealed 12, 15 and 16 μg/ml concentration
for Gram-positive test strains M. luteus, S. aureus and S.
epidermidis, respectively. In contrast, Gram-negative test
strains like Serratia marcescens and P. aeruginosa exhi-
bited MIC of 20 and 32 μg/ml respectively. Results of
heat stability assay of these lipopeptides fractions
revealed no reduction in activity even after exposing to
temperature of 100°C for 30 min (data not shown).
Mass spectrometry characterization of lipopeptides
The HPLC purified individual lipopeptide fractions were
collected, confirmed their purity by reinjection into
HPLC and used for the structure determination by
MALDI-TOF mass spectrometry. Results of analysis of
all HPLC fractions revealed the presence of various
lipopeptide species. The mass ion with m/z 984/985 Da
was observed in fractions of lipopeptides produced by all
Figure 3 Determination of antibacterial property of lipopeptide fractions. The assay performed against Gram positive S. epidermidis (A) and
Gram negative P. aeruginosa (B) bacteria. Data are the means calculated from three replicate experiments and vertical bars correspond to
standard deviations. Asterisk represents significant differences between treatments and negative control (0) with p<0.005 using one-way ANOVA
followed by Dunnett’s test. The results are presented as the mean of triplicates (n=3) ± SD.
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identification suggested that it had a β-hydroxylated C15
fatty acid. Additional GC-MS analysis of all HPLC puri-
fied fractions documented the presence of β-hydroxy
fatty acid with a chain length from C7 to C17. The frac-
tions Fr-c and Fr-e found commonly in strains S-3 and
S-11 showed high antimicrobial activity and the molecu-
lar mass determined for these lipopeptides were m/z
1495 and 1065, respectively (Figure 4). The fatty acid
analysis revealed that fractions Fr-c and Fr-e contained
β-hydroxy fatty acids with chain lengths C17 and C14
respectively, suggesting that these compounds belong to
the antimicrobial lipopeptide family fengycin and iturin
respectively. Further, the amino acid sequence obtained
for the fraction Fr-c (EOrnYTEVPEYV) confirmed it as a
member of fengycin family. The molecular mass and fatty
acid composition of fraction with m/z 1043 (Fr-a of sam-
ple S-6) assigned it to lipopeptide group surfactin. Other
antimicrobial mass ions produced by these strains include
m/z 607, 637, 679, 721, 746, 1153, 1180, 1522 and 1535.Discussion
Several reports have described that soil microbes are
worthy to be used as the source of different antimicro-
bial substances including peptides for versatile applica-
tions [24]. Most of the antimicrobial peptides produced
by diverse bacteria inhibit Gram-positive strains like
Listeria monocytogens but not Gram-negative [25].
Among the various peptides, lipopeptides are well
known to inhibit the growth of fungi and bacteria
including opportunistic pathogens. Consequently, naturally
produced antimicrobial lipopeptides have been receiving
increased attention due to their anti-infective nature with
wide antimicrobial spectrum. Besides the activity of natural
peptides, any chemical modifications in structure of these
lipopeptide are shown to improve their spectrum and
activity. To this effect, daptomycin, an anionic lipopeptide
has already been used for therapeutic applications [26].
While antimicrobial lipopeptides are produced by different
Gram-positive and Gram-negative bacteria, only lipopep-
tides produced by species of Pseudomonas and Bacillus
Table 1 List of masses observed in fractionated
lipopeptides from different samples obtained in positive
ion linear mode
Sample name HPLC fraction number Mass (m/z) SD






Sample S-4 Fr-a 679.57 0.0052
Fr-b 984.82 0.01




Sample S-6 Fr-a 1043.66 0.01
Fr-b 984.96 0.0059
Fr-c 637.01 0.0071
Sample S-7 Fr-a 1180.01 0.022
Fr-b 985.01 0.015
Fr-c 721.25 0.0011
Sample S-9 Fr-a 1536.16 0.0092
Fr-b 984.57 0.01
Sample S-10 Fr-a 1535.21 0.0074
Fr-b 984.21 0.0098





Sample S-12 Fr-a 679.23 0.003
Fr-b 984.14 0.0091
The calculations of standard deviation (SD) were done using MS Excel
Descriptive Statistics for each ion measurements (n=4), mi is the measured
mass and following is the formula:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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study several antimicrobial substances producing bacterial
strains were isolated from a fecal contaminated soil sample
and characterization of these substances revealed them as
antimicrobial lipopeptides.
The phenotypic features like Gram-negative staining,
catalase positive, oxidase negative, facultative anaerobic
growth and citrate utilization observed for all strains
suggested that they belong to the Enterobacteriaceae
family, usually observed in fecal matter. The 16S rRNA
gene sequence blast analysis and subsequent phylogentic
analysis assigned all strains to different species of thegenera Citrobacter and Enterobacter. Interestingly, though
strains S-5 and S-9 displayed high identity with E.
hormaechei and E. mori respectively in 16S rRNA gene
sequence, they only formed an out group to the cluster
comprised of different Enterobacter and Citrobacter
species (Figure 2). However, the overall topology of
neighbour-joining tree revealed the phylogenetic comple-
xity and discrepancies in 16S rRNA gene sequences of
strains belonging to the family Enterobacteriaceae. It was
also supported by the unusual inclusion of different
species belonging to genera Citrobacter and Enterobacter
in the same cluster suggesting the need to revisit the family
Enterobacteriaceae.
The antimicrobial lipopeptides typically contain a cyc-
lic or linear oligopeptide linked with a β-hydroxy fatty
acid tail of varied lengths [28]. Inhibition spectra of
these lipopeptides are influenced by the composition of
oligopeptide as well as fatty acid component [30,31].
Antimicrobial lipopeptides are largely produced by
Gram-positive bacteria like Bacillus sp. and are classified
into different families based on the composition of
oligopeptides and antibacterial or antifungal activities
[32]. Among the Gram-negative bacteria, Pseudomonas
is the only genus reported to produce antimicrobial
lipopeptides such as massetolide, viscosin [33], syrin-
gomycin [34], arthrofactin [35], pseudodesmins [36],
orfamide [16] and putisolvin [37]. In addition to these
lipopeptides, species like P. fluorescens was reported to
produce different massetolide analogues [33]. However,
lipopeptides produced by Gram-positive or Gram-negative
bacteria had different composition and so far no bacterial
strain has been reported to produce reciprocal combina-
tions of lipopeptide composition. Therefore, in the present
study we made an attempt to characterize lipopeptides
produced by the strains of genera Citrobacter and
Enterobacter.
The comprehensive mass spectral (MALDI-TOF MS
and GC-MS) analysis of HPLC purified antimicrobial
lipopeptides obtained from strains of Citrobacter and
Enterobacter revealed the occurrence of different
lipopeptide antibiotics belonging to groups like kursta-
kin, iturin, surfactin and fengycin, usually produced by
Gram-positive bacteria. Further, individual lipopeptide
belonging to a particular group shown to exhibit diffe-
rences in their amino acids [13,27], fatty acid chain
length or isomers of fatty acids and thus generating
various analogues with varied activity [13,33]. Accor-
dingly, lipopeptides of the present study showed diffe-
rences in fatty acid composition and also differed in
their antibacterial activity. Of the various lipopeptides,
the lipopeptide fraction Fr-b produced by all strains had
a molecular weight of 984/985 Da. Although amino acid
composition of this peptide identified it as kurstakin, it
differed in fatty acid composition (C15) when compared
Figure 4 MALDI MS spectrum of Fr-c and Fr-e from strainS-3 (identical spectrum is observed with the Fr-c and Fr-e of the strain S-11).
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with chain length of C11-C14, suggesting the lipopeptide
fraction (Fr-b) is an isoform of kurstakin. Further, differ-
ences in antimicrobial activity spectrum of these peptides
attributed to the fatty acid composition differences [20].
A variety of lipopeptides produced by strains Citrobacter
sp. strain S-3 and Enterobacter sp. strain S-11 were identi-
fied as lipopeptides belonging to iturin, kurstakin and
fengycin with unusual broad spectrum antibacterial acti-
vity. It is pertinent to mention that the fraction Fr-e of
strains S-3 and S-11, had an identical mass with the
lipopeptide reported by Swart and Merwe [38], therefore,
we have minimized further attempt to characterize the full
sequence as reported [β-NC14NYNQPNS]. Additionally,
identification of C14 fatty acid as the lipid content of the
fraction Fr-e also confirmed their classification under
iturins as they are known to contain a fatty acid chain
length of C14 to C16 [39] along with a cyclic peptide of
seven amino acids. Cyclic lipopeptide biosurfactants like
iturin, mycosubtilin, surfactin and kurstakin are largely
produced by species of Bacillus exhibiting antimicrobial
activity [12,28]. In fact, iturin and fengycin produced by B.
subtilis are recognized as potential biopharmaceutical
agents due to their antimicrobial and biosurfactant prop-
erties [14]. Although different types of lipopeptides varied
in their amino acid and/or fatty acid composition, they all
are usually thermostable, resistant to proteolytic enzymes
and inhibits the growth by altering the membrane integ-
rity. Similarly no reduction in antibacterial activity was
observed for fraction Fr-e upon exposing it to 100°C
temperature for 30 min suggesting it as heat stable. The
amino acid composition analysis of highly active lipopep-tide fraction (Fr-c) of strain S-3 and S-11 revealed the
sequence as R(C17)EOrnYTEVPEYV which corresponds
to linearized fengycin B’2, an isoform produced by a B.
subtilis strain [40]. Among the other lipopeptide fractions,
Fr-f (m/z 607.21 Da) and Fr-d (m/z 637.23 Da), produced
by strains S-3 and S-11, respectively, showed significant
antimicrobial activity, but could not be assigned to any
lipopeptide family as their molecular mass did not match
with any reported antimicrobial lipopeptides. Other mass
ions, except m/z 679 Da, produced by different strains did
not show significant antimicrobial activity against any test
strain. Although iturins, kurstakins, surfactins and
fengycins differed in composition, they followed the same
mechanisms such as involving pore formation on bacterial
membrane [41] or by other non-specific interactions with
the membrane [42] as a result of their antimicrobial
activity. Findings of this study, together with the fact that
the entire isolated strains belong to Citrobacter or Entero-
bacter and antimicrobial lipopeptide production ability,
suggests that they are possibly produced by these bacteria
as a part of defence mechanism to survive in complex
environments.
Conclusions
This is the first report on antibacterial lipopeptides pro-
duction by strains of Citrobacter and Enterobacter that
are part of the human intestinal flora and frequently
observed in food. The lipopeptides are exceedingly
useful molecules with potential applications in several
biotechnology sectors such as pharmaceutical, cosmetic,
preservation of food and dairy products. However,
engineering of these molecules is very important for our
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bial lipopeptides is expensive. Therefore, strains like S-3
or S-11 with ability to co-produce different antimicrobial
lipopeptides are very useful in biotechnology sector.
Increased lipopeptides production by these strains
through the optimization of physicochemical parameters
or transcriptional regulation of lipopeptide synthetase
gene clusters could be future insight for commercial
production.
Methods
Isolation of bacteria and identification
The bacterial isolates designated as S-3, S-4, S-5, S-6, S-
7, S-9, S-10, S-11 and S-12 were isolated from a fecal
contaminated soil sample. The soil sample used to iso-
late the strains was serially diluted and plated on nutri-
ent agar with the following composition (g/l): peptic
digest of animal tissue, 5.0; beef extract, 1.5; yeast
extract, 1.5; sodium chloride, 5.0; agar 15.0 (pH adjusted
to 7.2). Colonies with inhibition zone in their surroun-
dings were selected and streaked on to fresh nutrient
agar (NA, HiMedia, India) medium plates. Upon testing
their purity all isolates were preserved at -70°C for
further studies. Indicator strains used to test the activity
of lipopeptides were obtained from Microbial Type
Culture Collection and Genebank (MTCC), Chandigarh,
India. The test strains were grown on tryptone soya agar
(TSA) medium with the following composition (g/l):
pancreatic digest of casein, 15.0; papaic digest of soybean
meal, 5.0; sodium chloride, 5.0; agar 15.0 and the pH
adjusted to 7.2. All isolates producing antimicrobial lipo-
peptides were tested for phenotypic properties including
morphology, physiology and biochemical characteristics
using standard procedures. The identity of isolates was
also confirmed by using 16S rRNA gene sequence [43]
blast search analysis. All 16S rRNA gene sequences of the
nearest type strains were downloaded from the NCBI
database and aligned using CLUSTAL_W program of
MEGA version 5 [44]. The alignment was corrected
manually using the BioEdit sequence alignment editor
[45]. Pair-wise evolutionary distances were calculated with
the Kimura two-parameter [46] and a neighbour-joining
phylogenetic tree was constructed using the MEGA
version5.0. The stability of phylogenetic tree was assessed
by taking 1000 replicates. All sequences have been submit-
ted to EMBL database [accession nos. HF572835 -
HF572843].
Extraction of lipopeptides
Lipopeptides produced by all strains were isolated from
culture supernatant by a combination of acid and solvent
extraction procedure [47]. In brief, cells were pellet down
from the culture broth by centrifugation (13,000 × g) for
15 min at 4°C. The supernatant pH was adjusted to 2.0 byaddition of concentrated HCl and allowed to precipitate
at 4°C for 16 h. After centrifugation (13,000 × g) for 20
min at 4°C the precipitate was collected and extracted
with methanol by stirring for 2 h. The lipopeptide
containing methanol was collected after filtration and
vacuum-dried.Purification of lipopeptides
The lipopeptides extracted were dissolved in methanol
and fractionated by reverse phase- HPLC (Agilent 1100
series, CA, USA) with a ZORBAX 300-SB18 column
(4.6 mm × 250 mm, particle size 5 μm), at a flow rate of
1 ml/min. The solvent system used was (A) 0.1% aque-
ous TFA and (B) acetonitrile containing 0.1% TFA. The
following gradient of solvent B was used to run the
column: 0-60% for 0-45 min, 60-80% for 45-55 min and
80-100% for 55-60 min. All peptides eluted from the
column were monitored at 215 nm in a diode array
detector and all peaks obtained during HPLC were
collected using a fraction collector (GILSON, France)
that is coupled with the system. These fractions were
concentrated by speed vacuum and tested for their anti-
microbial activity. The fractions or peaks that showed
antibacterial activity were re-chromatographed in the
same column under similar conditions, except solvent B
was used as 100% acetonitrile with a gradient of 0-10%
for 30 min. The peptide concentration was determined
using the RP-HPLC conditions and calibrated with
surfactin (Sigma-Aldrich, St. Louis, USA).Antimicrobial assay and MIC determination
All fractions from the reversed phase HPLC were lyophi-
lized, redissolved in MilliQ water to test their antimicrobial
activity against S. epidermidis (MTCC435) and P. aerugino-
sa (ATCC27853) in a microtiter plate assay in triplicates.
To examine the bacterial growth or killing rate in the
presence of different fractions, bacterial cells were grown in
100 μl of Mueller-Hinton broth (MHB, HiMedia, India)
supplemented with fixed concentration (10 μg/ml) of each
fraction, at 37°C. Growth or killing rates were determined
by measuring OD at 600 nm. The OD values were conver-
ted into concentration of cells measured in CFU per milli-
litre (1.0 OD corresponded to 2.16 × 108 CFU/ml). The
MIC of selected biosurfactant/lipopeptide was evaluated for
strains S. aureus (MTCC1430), M. luteus (MTCC106) and
S. marcescens (MTCC 97) along with P. aeruginosa and S.
epidermidis by using a microtiter plate dilution assay in
triplicates as described earlier [48]. Test strains were
grown to logarithmic phase (between 0.3-0.4 OD)
under optimal conditions. The lowest concentration
inhibiting the growth of test strain without showing
any increase in absorption up to 48 h of incubation was
considered as MIC.
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The purified and active lipopeptides were analysed for
molecular mass and MS/MS sequencing by using a
Voyager time-of-flight mass spectrometer (Applied
Biosystems, Foster City, CA, USA). For MS/MS sequen-
cing, the lactone ring present in lipopeptide was cleaved
by incubating each peptide with 10% NaOH in methanol
at room temperature for 16 h. The cleaved peptide
obtained was lyophilized and again extracted with
methanol, and allowed for mass spectrometry analysis.
Spectra were recorded in the post-source decay (PSD)
ion mode as an average of 100 laser shots with a grid
voltage of 75%. The reflector voltage was reduced in
25% steps and guide wire was reduced 0.02–0.01% with
an extraction delay time of 100 ns.Fatty acid analysis by GC-MS
To analyze the fatty acid content associated with the
lipopeptides, the peptides (5 mg of each) were incubated
with 0.5 ml of 6 M HCl at 90°C for 18 h in sealed tubes
for acid hydrolysis. The fatty acids were extracted with
ether, treated with 0.95 ml methanol and 0.05 ml of 98%
H2SO4 at 65°C for 6 h. Finally, fatty acid methyl esters
were obtained with n-hexane extraction and analyzed on
GC-MS with a Clarus 500 GC (PerkinElmer, USA). The
carrier gas used was helium with a flow rate of 1.0 ml/min.
The column temperature was maintained at 120°C for 3
min and thereafter gradually increased (8°C/min) to 260°C.Statistical analysis
The statistical significance of the experimental results
was determined using one-way ANOVA followed by
Dunnett’s test. Values of p<0.05 were considered statisti-
cally significant. Prism version 5.0 was used for all statis-
tical analyses. The results are presented as the mean of
triplicates (n=3) ± SD.
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